Introduction
Drug-drug interactions (DDIs) represent a special category of adverse drug reactions (ADRs) in which the effects of one drug influence the effects of the other, thus either limiting effectiveness or inducing toxicity [1] . Overall, 1% of hospital admissions and 16% of admissions due to ADRs can be attributed to DDIs [2] . A higher number of DDIs is also significantly associated with longer hospitalization and higher treatment costs [1, 3, 4] . The probability of DDIs increases with the number of drugs prescribed to patients [5] [6] [7] [8] [9] . The incidence ranges from 13% for two drugs prescribed to 82% for seven or more drugs [10] .
There is a lack of studies on DDI incidence in patients with chronic heart failure (HF) and/or chronic obstructive pulmonary disease (COPD) and their clinical relevance. Polypharmacy is common in patients with these two conditions, but could be guideline-driven [11] [12] [13] . Comorbidity leads to prescribing more drugs on a regular basis if individual guidelines are implemented as appropriate. The complexity of the treatment regimen increases the probability of DDIs and prolongs hospitalization [1, [3] [4] [5] [6] [7] [8] [9] . A recent study that included 400 patients with chronic HF (median age 79; 55.5% men) reported a median of two major interactions on admission and three at discharge [8] . In general, the most common combinations of medications in which potential DDIs occurred during hospitalization were a combination of potassium-sparing diuretics and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and, second, a combination of aspirin and non-selective β-blockers in patients concomitantly treated with a β 2 agonist [1, 7, 8, 14] . To the best of our knowledge, no study has yet investigated DDIs in patients with COPD.
With little information at hand, we designed this study to evaluate the prevalence of DDIs at hospital admission and at discharge in patients with chronic HF and/or COPD. We also assessed the type of DDIs according to accepted classifications. In addition, we specifically analyzed interactions of potential clinical relevance according to estimated renal function.
Material and methods

Study design and patients
This was a retrospective study that included all consecutive patients who were discharged or died in the 6-month period from January 2011 to June 2011 with any discharge diagnosis of chronic HF or COPD at the Golnik University Clinic of Pulmonary and Allergic Diseases, Slovenia. The National Ethics Committee approved the protocol of this study (no. 77/11/11).
Patient discharge records were screened and selected if the diagnosis was coded chronic HF and/ or COPD according to International Classification of Diseases 10 (ICD 10) . This included diagnosis of chronic HF I50.0-I50.9, I42.0-I42.9, I11.0-I11.9, and COPD J44.0-J44. 9 . We excluded patients who had fewer than two medications prescribed on admission or discharge or both, who died during their hospital stay, or who had incomplete medical records regarding the medication prescribed either on admission or at discharge (Figure 1 ).
Data collection
The following data were extracted from medical documentation: patient characteristics (age, sex, concomitant diseases, heart rate, blood pressure), laboratory test results (serum creatinine concentration, hemoglobin concentration), number of diagnoses per patient, and length of hospital stay. Data about medication prescribed on admission and at discharge were retrieved from the discharge letter.
Several databases that describe and evaluate potential DDIs have been developed. The most common are the British National Formulary, Drug Interaction Facts, Drug-reax, ePocrates, Lexi-Interact, Pharmavista, and Stockley's Drug Interactions. The sensitivity and precision of these were evaluated taking Stockley's Drug Interactions database as the gold standard. The aim was to assess which database detects the most clinically significant potential DDIs and avoids reporting clinically non-significant interactions. None of the databases represented a completely reliable DDI reporting system in terms of sensitivity and specificity, but Lexi-Interact showed the best results in precision analysis despite a lower positive predictive value, which means that it also detects clinically non-significant potential DDIs. Pharmavista had lower sensitivity but a higher positive predictive value [15] . Our study used the Lexi-Interact database (available on UpToDate, 2012, release 20.8-C20.20) to evaluate patients' medication schemes for potential DDIs. The system provides information about the risk of DDI, and pharmacokinetic and pharmacodynamic effects and mechanisms of DDIs. It gives recommendations about managing DDIs and provides referenced literature. The software identified and classified DDIs according to their clinical relevance in the categories which are presented in Table I .
We analyzed type-C, -D, and -X potential interactions because they were considered clinically significant in previous studies [16] [17] [18] . We specifically analyzed combinations of drugs (ACE inhibitors/ARB and/or aldosterone antagonists) in patients stratified according to estimated renal function. Renal function was estimated from serum creatinine concentration using the abbreviated Modification of Diet in Renal Disease (MDRD) equation [19] .
Potential DDIs between drugs that were not listed in Lexi-Interact were evaluated by a panel of experts. The ML, TR, and KT reviewed drug pairs and evaluated DDIs. In the case of disagreement, the fourth member (AM) estimated the severity of DDIs. Evaluation was based on the drugs' product characteristics leaflets and by comparison to drugs of similar pharmacokinetic and/or pharmacodynamic profiles that are included in the Lexi-Interact database. Assessment included possible pharmacokinetic and pharmacodynamic interactions that were categorized into three levels of clinical significance, C, D, and X, in the same manner as in Lexi-Interact. These are presented in Table II .
Statistical analysis
Standard descriptive statistics was used to describe patient demographics. Mean and standard deviation or median and interquartile range were calculated for age, length of hospital stay, number of diagnoses, and number of drugs prescribed. Proportions were calculated for categorical data, which included sex and number of drugs on admission and discharge. The percentage of patients receiving cardiovascular and/or respiratory drugs of different pharmacologic classes was evaluated for patients with chronic HF, COPD, or both.
Normal distribution was evaluated with the Kolmogorov-Smirnov test. The average number of drugs and potential DDIs of different level per patient on admission and discharge were compared with a paired sample t-test. McNemar's test was used to compare the number of patients with at least one potential DDI of level C, D, or X on admission versus discharge. An independent t-test was used to compare the mean number of potential interactions of clinical significance level C, D, and X in the groups of patients with COPD or chronic HF, and patients with both medical conditions. Linear regression was used to calculate the association 
Results
Patient characteristics
We screened 4423 discharge letters and identified 1036 potentially eligible patients. Exclusion criteria were met in 258 patients: 74 had incomplete documentation on their medication on admission, 10 had incomplete documentation on their medication at discharge, 15 had incomplete documentation on their medication on admission and at discharge, 85 were prescribed fewer than two medications, and 74 died during their hospital stay. Thus, 778 patients were included in the study, of whom 361 had a diagnosis of chronic HF and 326 had COPD. Both diagnoses were present in 91 patients (Figure 1 ). The characteristics of the study population are presented in Table III .
The median age was 75 years (interquartile range (IQR) 67-82); 61% were men. The median number of drugs on admission was six (IQR 4-9) and at discharge seven (IQR 5-9) (p = 0.10). Table IV presents the number of patients with chronic HF and COPD receiving drugs from the most common pharmacological classes of cardiovascular and respiratory drugs on admission and at discharge. Figure 2 compares the proportions of all patients (groups of chronic HF patients, COPD patients, and patients with both diagnoses are presented in Figures 3-5) with various numbers of drugs prescribed on admission and at discharge. In patients with only chronic HF or only COPD, Table V . There were significantly more patients with at least one potential DDI of clinical significance level C and X at discharge than on admission (p = 0.01).
The most common drug combinations flagged with level C, D, and X potential DDI at hospital discharge are presented in Tables VI-VIII, respectively. We identified 485 different drug combinations with potential DDIs; 373 of these were DDIs of clinical significance C (Table VI) . The most common were between a loop diuretic and a β 2 receptor agonist (6.6% of cases), followed by a combination of two β 2 receptor agonists (6%). At hospital discharge, 98 level-D interactions were identified (Table VII) , the most common being those between a β-blocker and an α antagonist (12.3%), followed by cases of calcium carbonate and bisphosphonate combination (7.1%) and ACE inhibitor and allopurinol combination (6%).
Forty-five cases of potential DDIs of clinical significance X at hospital discharge, which included 14 different drug combinations, are presented in Table VIII . In the majority of cases (63%), there was an interaction between a non-selective β-blocker and a β 2 agonist. The most common drugs involved in potential DDIs of clinical significance level X were quetiapine (4 cases), clozapine (2 cases), and haloperidol (2 cases). Out of 778 patients, 14 were prescribed quetiapine, four clozapine, and 16 haloperidol.
Patients with chronic HF had significantly more level-C and level-D interactions when compared to patients with COPD: 8.18 ±5.24 vs. 4.68 ±4.43 (p < Laboratory data: (22) 114 (32) 32 (10) 23 (25) Atrial fibrillation 228 (29) 162 (45) 31 (10) 23 (25) Ischemic heart disease 51 (7) 27 (7) 18 (6) Calcium channel blockers 97 (27) 94 (26) Digoxin 64 (18) 87 (24) Aldosterone antagonist 62 (17) 76 (21) Angiotensin receptor blockers 57 (16) 60 (16) α-Receptor antagonist 30 (8) 27 (7) Patients with COPD (n = 326) (Table IX) .
For the group of patients with chronic HF (n = 452), we evaluated a possible interaction between ACE inhibitor and/or ARB with spironolactone according to the estimated renal function. eGFR was available for 379 (84%), and 77 of these had concomitant COPD. Patients were classified into three groups: 36 patients had eGFR ≤ 30 ml/ (min × 1.73 m 2 ), 176 between 30 and 59 ml/(min ), and 167 ≥ 60 ml/(min × 1.73 m 2 ). Three percent of patients with eGFR ≤ 30 ml/ (min × 1.73 m 2 ) were prescribed an ACE inhibitor and/or ARB and spironolactone, 72% only an ACE inhibitor or ARB, and 3% only spironolactone at discharge. A combination of ACE inhibitor and/or ARB and spironolactone was prescribed in 22% of patients with eGFR between 30 and 59 ml/(min × 1.73 m 2 ) and in 13% of patients with eGFR ≥ 60 ml/ (min × 1.73 m 2 ) at discharge ( Figure 7) . Only 3 out of 452 patients were concomitantly prescribed an ACE inhibitor and an ARB. None of these had reduced renal function.
Discussion
This is the first study to report on potential DDIs in patients with chronic HF and/or COPD. The DDIs per patient increased from admission to discharge and were more common in patients with concomitant chronic HF and COPD. The most common type-X potential DDI was a combination of β-blocker and β 2 agonist, which may reflect better guideline implementation rather than poor clinical practice. In many patients with impaired renal function, greater caution regarding renin-angiotensin-aldosterone antagonist use should be considered.
The study population reflects the patient population from daily clinical practice and the population included in other studies [20] [21] [22] . Twenty percent of patients with chronic HF had concomitant COPD, which is similar to the proportion of patients included in the study assessing the prevalence of these two conditions [22] .
In our study, only 26% of discharged COPD patients were prescribed a short-acting β 2 agonist (SABA), 59% a combination of SABA and ipratropium, and 28% theophylline, which is not in line with other studies conducted on this population in Slovenia. A study on COPD patients in the same hospital setting showed that 91% of patients were prescribed a SABA, 64% a combination of SABA and ipratropium, and 64% theophylline [21] . This shows poor adherence to treatment guidelines in our setting. In the cohort of patients with chronic HF, 81% of patients were prescribed a diuretic, 62% an ACE inhibitor, 16% an ARB, and 57% a β-blocker. These numbers did not increase markedly during the hospital stay, although this would be in accordance with treatment guidelines for chronic HF. In another study that included patients with chronic HF and concomitant COPD, 98% were prescribed furosemide, 77% an ACE inhibitor/ARB, and only 12% a β-blocker [22] . The number of drugs prescribed per patient did not significantly increase from admission to discharge, and thus neither did the average number of potential DDIs. Similar findings were observed in a Swiss study that was conducted on a medical ward and showed that on average patients were taking four medications on admission, 11 during hospitalization, and six at hospital discharge. Consequently, the frequency of potential DDIs was 30% on admission, 56% during hospitalization, and 31% at discharge. Three hundred and ninety-six patients out of 697 (56.8%) had at least one potential DDI at discharge, 47% of those due to treatment change during the hospital stay [7] . Despite no change in the number of all potential DDIs per patient, the number of type-C and type-X interactions increased from admission to discharge (Table V) . Furthermore, a comparison between groups (Figure 6 ) showed that the number of level-C and level-X interactions significantly increased only in patients with concomitant chronic HF and COPD, but not in patients with chronic HF and COPD only. In the case of type-X interactions, this may be explained by the addition of a β 2 agonist for the treatment of COPD in patients already receiving a non-selective β-blocker due to chronic HF. This is actually implementation of guidelines because COPD is not a valid contraindication for β-blockers [12] . The number of clinically significant potential DDIs of levels C, D, and X was associated with the number of diagnoses and consequently with the number of drugs patients were receiving. Although this had been reported previously [4, 6, 17 , 23], we did not see any association with the length of stay as reported by Moura et al. [1] .
In our study, at least one potential DDI of clinical significance level C, D, or X at discharge was found in 94.5%, 30.2%, and 5% of the total patient population, respectively. This prevalence is higher than presented in a study that assessed the prevalence of DDIs in patients with arterial hypertension in a community setting, which reported the prevalence of DDIs of clinical significance at level C to be 83.3%, level D 16.3%, and level X 0.4% [17] . One possible reason for the higher rates observed in our study lies in the comorbidity and polypharmacy of our patient population. Our cohort of patients was prescribed a median number of seven drugs at discharge, whereas the patients with arterial hypertension had a median of five [17] .
The most prevalent potential DDIs of clinical significance C included a combination of antihypertensive drugs, which may cause hypotension. The combination of more than one drug for lowering blood pressure is common and is a guideline-recommended treatment to reach target blood pressure. The combination of ACE inhibitors (or ARB), a β-blocker, and a diuretic is also recommended by ESC guidelines for treatment of chronic HF [12] . Despite the potential DDIs, the average systolic and diastolic blood pressures of the study population are still above the recommended target blood pressure. In the case of DDIs of clinical significance D, therapy modification needs to be considered. The most common drug combination that causes potential DDI of clinical significance D was a combination of β-blocker and α receptor antagonist (12.2%).
There are also significant differences between the number of potential DDIs in patients with chronic HF and COPD. Chronic HF patients have more type-C and type-D interactions than COPD patients, which may reflect more evidence about life-prolonging drugs established for patients with chronic HF [11, 12] . Guidelines may also be the main reason for more DDIs in patients with concomitant chronic HF and COPD. Although this likely reflects better clinical practice, it is associated with greater risk of potentially significant DDI and should be handled accordingly.
As mentioned previously, more type-X potential DDIs were found in patients with concomitant chronic HF and COPD and most of these were between a non-selective β-blocker (carvedilol) and a β 2 receptor agonist (64%). In clinical practice, COPD is not a contraindication for β-blocker use, and abundant evidence supports β-blocker use in patients with chronic HF. Furthermore, several studies have demonstrated that cardioselective β-blockers have fewer pulmonary side effects than non-selective ones [24] [25] [26] [27] [28] and should be the preferred agent of choice in these patients [12] . However, a study that assessed that tolerability of carvedilol in patients with chronic HF and concomitant COPD showed that peak expiratory flow rate measured before and 2 h after administration of carvedilol increased by 17% (p = 0.04). This effect might be due to decreased airflow obstruction, peribronchial fluid, and filling pressures on improved cardiac function [24] . This is a small study, but it raises the question of whether this combination is indeed contraindicated. Furthermore, it should be mentioned that the beneficial effects of β-blockers extend beyond the cardiac system because they have beneficial effects on the body and glucose metabolism [29] [30] [31] .
Antipsychotic drugs are commonly involved in potential DDIs of significance level X. Quetiapine, clozapine, haloperidol, risperidone, and phenothiazine antipsychotics may enhance the QTc-prolonging effect of other drugs or each other if used together. This is due to altered activity of cytochrome P450 activity, and consequently plasma concentrations of co-administered drugs may be increased or decreased [32] . In our study, only a small proportion of patients were prescribed these drugs. Although not frequent, these combinations should be avoided whenever possible.
The use of the DDI database provides only a general estimate of clinical importance, which needs to be tailored to the individual patient, particularly to laboratory parameters and comorbidities. Renal (dys)function is a major determinant of pharmacological treatment in patients with chronic disease [33] . Clinicians must be particularly cautious with spironolactone, which has been associated with increased prevalence of hyperkalemia and increased mortality [34] . Generally, aldosterone antagonists should be withheld in patients with eGFR < 30 ml/(min × 1.73 m 2 ) and used only under close monitoring if eGFR is between 31 and 60 ml/(min × 1.73 m 2 ) [33] . Clinical practice across Europe [20] , however, is not following this advice and our study reports similar results. In two (3%) patients with eGFR < 30 ml/(min × 1.73 m 2 ), we should change combination therapy to monotherapy due to an increased risk of arrhythmia, and in 38 (22%) patients regular checks of serum electrolytes and markers of renal function should be advised in specialized outpatient settings. However, 72% of patients with eGFR < 30 ml/(min × 1.73 m 2 ) were prescribed only an ACE inhibitor or ARB and 3% only spironolactone. Surprisingly, in chronic HF patients with normal renal function, where the combination of these drugs would be preferred, this combination was found only in 13% of patients.
The main limitations of our study were its retrospective design, diagnoses from discharge letters, and incomplete information on the medication prescribed. However, the prevalence of missing data is still lower than observed in other studies [23] . Another limitation is the evaluation of potential DDIs with software, which provides only a general estimate of clinical significance. Based on previous research, this is the most frequently used software and provides information with the highest sensitivity, although it detects potential DDIs that may not be of high clinical significance [15] . All DDIs should therefore be interpreted individually; from available data, we have adjusted the Lexi DDI for renin-angiotensin-aldosterone modulators according to patient renal function. The DDIs are also influenced by daily doses and patient characteristics (e.g. renal function, blood pressure, heart rate, etc), and we controlled for this only partially ( Figure 7 ). The electronic systems used for identification of potential DDIs in this study and in clinical practice do not consider daily dose; per study design we therefore did not control for daily dose, which may not be so relevant for identification of potential DDIs but certainly is crucial for evaluation of clinical relevance, which however was beyond the scope of this study.
In conclusion, there is a high prevalence of DDIs in patients with chronic HF and COPD. This appears to be due to the high number of medications required by comorbidity. Some of these could be avoided, but the majority of them likely reflect better guideline implementation rather than poor clinical practice. Clinical significance, however, should be interpreted individually before any actions are taken. An adjustment for renal function using eGFR can stratify patients for the risk of worsening renal function and hyperkalemia risk. Previous experience about decisions in clinical practice, particularly for the use of β-blockers, show that clinicians are reluctant to withdraw life-saving medication and prefer to either delay or stop up-titration [13, 35] . The literature about safe use in patients with concomitant chronic HF and COPD is steadily growing and supports the use of a cardioselective β-blocker with fewer side effects and no significant change in lung function [25, 26] . This is particularly important because β-blockers have many ancillary effects, including glucose and body metabolism [29, 30] , which could prevent body wasting and poor prognosis [36] .
Discussions about pharmacological management, DDIs, and the risk of side effects should always include patients and their caregivers. Implementation of non-pharmacological advice and close self-management [12, 34] with reporting to medical professionals is crucial for early recognition of evolving complications and can prevent irreversible consequences. Ideally, patients should be managed in specialized outpatient settings at least during their vulnerable periods (e.g., after hospitalization and during medication regimen modification) because this appears to improve patient knowledge and prognosis [37] [38] [39] .
